Serbia: Europe's Emerging Clinical Trial Powerhouse

Serbia is rapidly distinguishing itself as a premier European destination for clinical trials, offering a unique synergy of robust regulatory alignment, operational excellence, and remarkable patient engagement. Sponsors benefit from exceptionally high recruitment and retention rates—often exceeding 90%—driven by a centralized healthcare system and highly motivated investigators. With a strong specialization in oncology, metabolic diseases, and cardiology, Serbia provides reliable, high-quality data within a cost-effective framework that maintains EU standards.

Navigate the streamlined Serbian regulatory pathway with confidence, supported by a transparent approval process and predictable timelines. This report, presented by Palleos, a full-service CRO with deep regional expertise, provides an in-depth analysis of Serbia's clinical trial landscape, including detailed metrics on therapeutic areas, phase distribution, and practical guidance on permits and compliance. Download the full report to unlock the complete strategic advantages of conducting your next clinical trial in Serbia.